COMMUNIQUÉS West-GlobeNewswire
-
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
23/08/2024 - 23:00 -
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
23/08/2024 - 23:00 -
IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
23/08/2024 - 23:20 -
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
24/08/2024 - 00:45 -
Capital and Business Alliance Formed Between MEDIROM MOTHER Labs and NFES Technologies
24/08/2024 - 03:12 -
Le KFSHRC propose des programmes de recherche innovants aux futurs leaders du secteur de la santé
24/08/2024 - 11:43 -
KFSHRC Sets New Global Standards in Digital Healthcare Education
24/08/2024 - 12:21 -
Brains Bioceutical s’apprête à obtenir l’une des premières certifications CEP pour le cannabidiol au monde auprès de la Direction européenne de la qualité du médicament et soins de santé
23/08/2024 - 04:06 -
Burning Rock Reports Second Quarter 2024 Financial Results
23/08/2024 - 05:59 -
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma
23/08/2024 - 07:00 -
Vistin Pharma ASA: Second quarter and first half 2024 financial results
23/08/2024 - 07:40 -
PCI Biotech: Invitation to first half interim 2024 results presentation
23/08/2024 - 09:36 -
KFSHRC Empowers Future Healthcare Leaders with Innovative Research Programs
23/08/2024 - 11:46 -
AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
23/08/2024 - 13:00 -
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
23/08/2024 - 13:00 -
OKYO Pharma Announces Chairman Acquires Shares
23/08/2024 - 13:00 -
Repligen Corporation to Present at Wells Fargo Healthcare Conference
23/08/2024 - 13:30 -
European Commission approves BALVERSA®▼ (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma
23/08/2024 - 13:30 -
WORK Medical Technology Group LTD Announces Pricing of Initial Public Offering
23/08/2024 - 14:00
Pages